[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

DOI: 10.7150/thno.13702

Keywords: Neuroendocrine tumour, somatostatin receptor, peptide receptor, radiotherapy, radionuclide therapy, somatostatin analogue.

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text